All In Biotech

Drug Trial Radar · NCT04246359

Rituximab and Pegylated Interferon α-2b in Patients With Indolent B-cell Lymphoma

Safety and Activity of Rituximab(HLX01) in Combination With Pegylated Interferon α-2b in Patients With Newly Diagnosed Advanced Indolent B-cell Lymphoma: a Single-arm, Multicenter, Phase 2 Study

Last checked: Nov 19, 2026Latest source record: Apr 7, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

52

Planned (sponsor's estimate)

Start

Jan 15, 2020

Primary completion

Jun 16, 2022

Study completion Jan 16, 2023

Sponsor

Lead sponsor
Huiqiang HuangAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 29, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A phase 2 open label study to evaluate safety and activity of Rituximab(HLX01) in combination with Pegylated interferon α-2b in patients with newly diagnosed advanced indolent B-cell lymphoma.

Conditions

  • Lymphoma, B-Cell

Interventions

  • Rituximab BiosimilarDrug

    To evaluate the short-term objective efficacy of HLX01 combined with Pegylated Interferon α-2b in patients with advanced idolent B-cell lymphoma.

  • Pegylated Interferon α-2bDrug

    To evaluate the short-term objective efficacy of HLX01 combined with Pegylated Interferon α-2b in patients with advanced idolent B-cell lymphoma.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR)、Complete Remission Rate (CRR)、Partial Remission Rate (PRR)Time frame: Up to 21 weeks
  2. HBsAg clearance rate and anti-Hbs antibody positive rate in patients with chronic hepatitis B at 72 weeksTime frame: Up to 72 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Department of Medical Oncology, Sun Yat-sen University Cancer Center,

    Guangzhou, Guangdong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.